公开(公告)号：US20180291079A1

公开(公告)日：2018-10-11

申请号：US15575707

申请日：2016-05-20

Applicant: Cellectis

Inventor： Julianne SMITH ,  Cècile SCHIFFER-MANNIOUI

IPC: C07K14/725 ,  C07K14/705 ,  C07K14/735 ,  C07K16/30 ,  C12N5/0783

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a GD3 monoclonal antibody, conferring specific immunity against GD3 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating solid tumors such as melanomas, carcinomas or liquid tumor such as T-cell lymphoblastic leukemia.

公开(公告)号：US20170226183A1

公开(公告)日：2017-08-10

申请号：US15329530

申请日：2015-07-29

Applicant: CELLECTIS

Inventor： Cècile SCHIFFER-MANNIOUI

IPC: C07K14/735 ,  C07K16/28

CPC classification number: C07K14/70535 ,  C07K16/2803 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/70

Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs, which are made specific to the antigen ROR1. Such CARs aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen ROR1. The alpha, beta and gamma polypeptides composing these CARs are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer, especially chronic lymphocytic leukemia or solid tumors.

公开(公告)号：US20170283497A1

公开(公告)日：2017-10-05

申请号：US15329932

申请日：2015-07-29

Applicant: Cellectis

Inventor： Cècile SCHIFFER-MANNIOUI

IPC: C07K16/28 ,  C12N5/10 ,  C07K16/30 ,  C12N15/62 ,  A61K35/17 ,  C07K14/705

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a ROR1 monoclonal antibody, conferring specific immunity against ROR1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as breast, colon, lung, and kidney tumors

公开(公告)号：US20170275374A1

公开(公告)日：2017-09-28

申请号：US15506643

申请日：2015-09-03

Applicant: CELLECTIS

Inventor： Cècile SCHIFFER-MANNIOUI

IPC: C07K16/30 ,  C12N5/0783 ,  C07K14/725 ,  C12N5/078 ,  C07K14/705 ,  C07K19/00

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a 5T4 monoclonal antibody, conferring specific immunity against 5T4 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as colon, stomach, and ovarian tumors.

公开(公告)号：US20160145337A1

公开(公告)日：2016-05-26

申请号：US14891296

申请日：2014-05-12

Applicant: CELLECTIS

Inventor： Roman GALETTO ,  Julianne SMITH ,  Andrew SCHARENBERG ,  Cècile SCHIFFER-MANNIOUI

IPC: C07K16/28 ,  C07K14/725 ,  C07K14/705

CPC classification number: A61K35/17 ,  A61K38/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/28 ,  C07K16/2803 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/74 ,  C12N5/0636 ,  C12N2501/39 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2502/99 ,  C12N2510/00

Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.

Abstract translation: 本发明涉及嵌合抗原受体（CAR）。 CAR能够将免疫细胞特异性和反应性转向利用配体结合结构域性质的选定靶标。 特别地，本发明涉及嵌合抗原受体，其中细胞外配体结合是衍生自CD19单克隆抗体的scFV，优选4G7。 本发明还涉及多核苷酸，编码所述CAR的载体和在其表面表达所述CAR的分离的细胞。 本发明还涉及用于在其表面上工程化表达4G7-CAR的免疫细胞的方法，其赋予转导细胞上延长的“活化”状态。 本发明特别可用于治疗B细胞淋巴瘤和白血病。